Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
As a triple-acting peptide targeting GLP-1, GIP, and glucagon receptors, Retatrutide work
Our experienced clinicians monitor your progress, labs, and hormone balance to ensure your dosage is safe and effective
Being aware of these patterns helps patients and healthcare providers interpret lab results accurately and ensures that treatment remains both safe and effective
YOU MAY UNSUBSCRIBE AT ANY TIME.
Mechanism of action what the published research describes Retatrutide (LY3437943, originally developed by Eli Lilly) is a long-acting fatty-acid-conjugated peptide that engages three incretin and metabolic receptors simultaneously: GLP-1 receptor the same target as semaglutide and the GLP-1 component of tirzepatide
